EMD Serono Inc., a Rockland-based subsidiary of Merck KGaA of Germany, said today that a third trial for its investigational cancer drug cilengitide did not meet its primary endpoint in patients with newly diagnosed glioblastoma.
The trial was planned and is being conducted in partnership with the European Organization for Research and Treatment of Cancer, officials said, adding detailed trial results will be submitted for presentation at the American Society of Clinical Oncology 2013 Annual Meeting and publication in a peer-reviewed journal.
Patient safety in the trial was monitored frequently by an independent data-monitoring committee and no new or unexpected safety concerns were noted, officials said. In prior clinical studies, the most frequently reported adverse events the investigators considered to be attributed to cilengitide included nausea and fatigue.
Glioblastoma is the most common and deadliest of malignant primary brain tumors in adults.
"The results ... are disappointing, especially for people who are fighting this devastating and difficult to treat cancer. Over the coming months, we intend to analyze the data sets and ensure appropriate public disclosure of key information that will serve future scientific research related to targeted therapies in oncology," said Dr. Annalisa Jenkins, head of global drug development for Merck Serono, in a statement. "We remain committed to advancing our pipeline and developing new treatment options in oncology for patients with high medical need."
Anda sedang membaca artikel tentang
EMD Serono’s brain tumor drug disappoints in clinical trial
Dengan url
http://newsreviewsis.blogspot.com/2013/02/emd-seronoas-brain-tumor-drug.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
EMD Serono’s brain tumor drug disappoints in clinical trial
namun jangan lupa untuk meletakkan link
EMD Serono’s brain tumor drug disappoints in clinical trial
sebagai sumbernya
0 komentar:
Posting Komentar